ACADIA Pharmaceuticals (NASDAQ:ACAD) Now Covered by Analysts at Deutsche Bank Aktiengesellschaft

Stock analysts at Deutsche Bank Aktiengesellschaft started coverage on shares of ACADIA Pharmaceuticals (NASDAQ:ACAD - Get Free Report) in a report released on Tuesday, MarketBeat Ratings reports. The firm set a "hold" rating and a $22.00 price target on the biopharmaceutical company's stock. Deutsche Bank Aktiengesellschaft's target price would suggest a potential upside of 9.91% from the stock's previous close.

A number of other brokerages have also recently commented on ACAD. Needham & Company LLC reissued a "buy" rating and issued a $28.00 price target on shares of ACADIA Pharmaceuticals in a research report on Thursday, November 7th. HC Wainwright restated a "buy" rating and issued a $27.00 price objective on shares of ACADIA Pharmaceuticals in a research note on Thursday, November 7th. Guggenheim downgraded shares of ACADIA Pharmaceuticals from a "buy" rating to a "neutral" rating and dropped their target price for the stock from $23.00 to $20.00 in a report on Friday, January 3rd. Finally, StockNews.com downgraded shares of ACADIA Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a report on Thursday, November 14th. Eight investment analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $24.00.

ACADIA Pharmaceuticals Trading Up 1.2 %

ACADIA Pharmaceuticals stock traded up $0.25 during trading hours on Tuesday, hitting $20.02. 557,256 shares of the stock traded hands, compared to its average volume of 3,020,861. The firm's 50-day moving average price is $17.95 and its two-hundred day moving average price is $16.68. The company has a market cap of $3.33 billion, a PE ratio of 25.76 and a beta of 0.37. ACADIA Pharmaceuticals has a one year low of $14.15 and a one year high of $26.56.

Insider Transactions at ACADIA Pharmaceuticals

In other news, CFO Mark C. Schneyer sold 10,259 shares of the firm's stock in a transaction that occurred on Tuesday, November 19th. The shares were sold at an average price of $16.81, for a total transaction of $172,453.79. Following the transaction, the chief financial officer now directly owns 53,302 shares of the company's stock, valued at approximately $896,006.62. This trade represents a 16.14 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider James Kihara sold 4,073 shares of the firm's stock in a transaction that occurred on Tuesday, November 19th. The stock was sold at an average price of $16.81, for a total transaction of $68,467.13. Following the transaction, the insider now directly owns 19,863 shares in the company, valued at approximately $333,897.03. This trade represents a 17.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 24,661 shares of company stock valued at $414,551. 28.30% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On ACADIA Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the business. SG Americas Securities LLC boosted its stake in shares of ACADIA Pharmaceuticals by 380.3% during the fourth quarter. SG Americas Securities LLC now owns 2,483,731 shares of the biopharmaceutical company's stock valued at $45,576,000 after purchasing an additional 1,966,607 shares in the last quarter. Barclays PLC boosted its stake in shares of ACADIA Pharmaceuticals by 126.2% during the third quarter. Barclays PLC now owns 277,565 shares of the biopharmaceutical company's stock valued at $4,269,000 after purchasing an additional 154,854 shares in the last quarter. B. Metzler seel. Sohn & Co. Holding AG bought a new position in shares of ACADIA Pharmaceuticals during the third quarter valued at approximately $483,000. Burney Co. bought a new position in shares of ACADIA Pharmaceuticals during the fourth quarter valued at approximately $6,953,000. Finally, BNP Paribas Financial Markets boosted its stake in shares of ACADIA Pharmaceuticals by 259.0% during the third quarter. BNP Paribas Financial Markets now owns 223,618 shares of the biopharmaceutical company's stock valued at $3,439,000 after purchasing an additional 161,331 shares in the last quarter. 96.71% of the stock is currently owned by institutional investors.

ACADIA Pharmaceuticals Company Profile

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.